PET radiopharm proposed reg "unjustifiably" reverses FDA nuclear pharmacy policy -- medical groups.
PET RADIOPHARM PROPOSED REG "UNJUSTIFIABLY" REVERSES FDA POLICY, ASHP (the American Society of Health-system Pharmacists), the American Pharmaceutical Association and the American College of Nuclear Physicians/Society of Nuclear Medicine maintain in a July 27 joint letter to FDA Commissioner Kessler. The coalition wrote to express its "profound concern regarding the direction the FDA is taking in regulating PET (positron emission tomography) radiopharmaceuticals."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth